| Wednesday 16 February 2022 Good morning Voornaam,
Things at Oceana are starting to smell like a rotten fish that has been lying in the sun for a week. After the results of the legal investigation into the company's accounting were downplayed by the company, we've seen the CFO leave the building and now the CEO and another executive director as well. Very few details are being provided by the company in the SENS announcements. The share price finally took a knock in response to all this, down 4.6% yesterday. A replacement CEO has been announced in the form of Neville Brink, who has been with the group since 1995. At this stage, the market is just looking for answers on what is actually going on.
The Steinhoff settlement process kicked off yesterday, which means that eye-watering amounts of money changed hands. This puts Steinhoff's previous issues to bed once and for all. The group will now need to focus on improving its balance sheet and driving its operations. There is very little room for error, as the group is still carrying a lot of debt.
Distell has successfully cleared the first hurdle in the deal process. The various resolutions under the scheme of arrangement for the Heineken deal were approved at a scheme meeting held yesterday. There's still a long way to go in the process and interested parties should refer to the deal circular for the full transaction timetable. The great unknown is the Competition Commission, with that process to be followed in coming months.
Discovery has announced a new initiative called Amplify Health, a Pan-Asian health InsurTech business in partnership with AIA Group, a market-leading insurance group in Asia. If it has Tech in the name, it must be exciting right? In this case, Pan-Asian means Asia excluding China, Hong Kong and Macau, as Discovery already has an exclusive relationship in those countries with Ping An Health Insurance.
Long story short: Discovery's Vitality and other innovations will be used in this joint venture through a working relationship that Discovery calls the "Shared-Value Insurance" model. It's a clever model as it lets Discovery monetise the intellectual property it has already developed, while tapping into markets that would otherwise be difficult to access.
Discovery will hold a 25% stake in the joint venture and will earn additional income for the assignment of IP ownership and transfer of expertise. Jonathan Broomberg, former CEO of Discovery Health and current CEO of Vitality Health International, will be the founding CEO of Amplify Health. Despite all this happy news, the share price only closed 1.6% higher on the day.
Reunert will be moving ahead with the restructure of its B-BBEE ownership and the establishment of an employee share ownership programme. The various resolutions required for the deals were passed at a gen eral meeting held yesterday.
Zeder shareholders need to check their emails, as the circular for the disposal of The Logistics Group has been sent out. The meeting to vote on the transaction will be held on 15 March.
Today's feature articles are on Spar's sales update for the festive period and BHP's results for the six months to December 2021, which culminated in a record interim dividend. Currency Assist has also weighed in on the debate around whether funds should be moved offshore for diversification as part of a wealth creation strategy.
Finally, make sure you listen to Episode 62 of Magic Markets. This was a favourite of mine, as we tapped into the brilliant mind of Afrimat CEO Andries van Heerden. Afrimat has a formidable track record on the JSE, which is especially impressive as it has been achieved in the mining sector which is one of the hardest places to play. Find out the secrets to success here.
Have a wonderful Wednesday!
The Finance Ghost
|
|---|
|
|---|
Local and Offshore Market News |
|---|
|
|---|
| Disclaimer
Our content is intended to be used and must be used for informational purposes only. You must do your own analysis before executing any investments or strategic decisions, based on your own circumstances. We do not provide personalised recommendations or views as to whether an investment approach or corporate strategy is suited to the needs of a specific individual or entity. You should take independent financial advice from a suitably qualified individual who gives due regard to your personal circumstances.
Whilst every care is taken, we accept no responsibility or liability for any errors or omissions in any of our content.
The views, thoughts and opinions expressed in our content belong solely to the author or quoted individuals and/or entities, and not necessarily to the author's employer, organisation, committee or other group or individual, or any of our affiliates or brand partners. |
|---|
|
|---|
|
|
